Compare QBTS & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QBTS | VIR |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 773.5M |
| IPO Year | N/A | 2019 |
| Metric | QBTS | VIR |
|---|---|---|
| Price | $26.21 | $6.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $30.08 | $25.73 |
| AVG Volume (30 Days) | ★ 31.6M | 1.8M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,144,000.00 | $16,860,000.00 |
| Revenue This Year | $194.34 | N/A |
| Revenue Next Year | $56.23 | $48.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 156.20 | N/A |
| 52 Week Low | $3.71 | $4.16 |
| 52 Week High | $46.75 | $14.45 |
| Indicator | QBTS | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 49.19 | 61.51 |
| Support Level | $21.32 | $6.49 |
| Resistance Level | $29.15 | $6.89 |
| Average True Range (ATR) | 2.16 | 0.47 |
| MACD | 0.67 | 0.06 |
| Stochastic Oscillator | 64.83 | 83.17 |
D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.